Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-90006 · 2 trials · 2 indications
Number of participants with adverse events
| Arm | Type | Description |
|---|---|---|
| CC-90006; Dose level 1 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 2 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 3 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 4 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| Placebo | PLACEBO_COMPARATOR | Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose Level 5 | EXPERIMENTAL | CC-90006 will be administered by subcutaneous injection in the abdomen |
| Name | Type | Description |
|---|---|---|
| CC-90006 | DRUG | CC-90006 |
| Placebo | OTHER | Placebo |
Inclusion Criteria: The following is a summary of the inclusion criteria: 1. Males or non-pregnant females between the ages of 18 and 60 years (inclusive) at the time of signing the ICF, and be willing to adhere to the requirements of contraception use throughout the study. 1. Female subjects ...
CC-90006 is an investigational small molecule being studied for use in healthy volunteers and in patients with mild to moderate plaque-type psoriasis. It is currently in Phase 1 clinical development and is not approved by the FDA.
CC-90006 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY on the New York Stock Exchange.
CC-90006 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in healthy volunteers and one in patients with mild to moderate plaque-type psoriasis. The drug is investigational and has not been approved.
CC-90006 has been studied in two completed Phase 1 trials. NCT02934269 evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics in 40 healthy subjects in the United States. NCT03337022 evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in 34 subjects with mild to moderate plaque-type psoriasis in the United States and Canada.
No alternative names for CC-90006 have been disclosed. It is identified solely by its code name CC-90006 in clinical trial registries and by its developer, Bristol-Myers Squibb.